nadp has been researched along with Neuralgia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asmis, R; Dietz, AK; Forsthuber, TG; Maroof, AM; Robinson, RR | 1 |
| Cuzzocrea, S; Doyle, T; Esposito, E; Jacobson, KA; Janes, K; Salvemini, D; Tosh, DK | 1 |
1 review(s) available for nadp and Neuralgia
| Article | Year |
|---|---|
The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.
Topics: Adenosine Triphosphate; Animals; Cell Communication; Central Nervous System; Disease Progression; Humans; Inflammation; Multiple Sclerosis; NADP; Neuralgia; Neuroglia; Neurons | 2019 |
1 other study(ies) available for nadp and Neuralgia
| Article | Year |
|---|---|
A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Antineoplastic Agents, Phytogenic; Cytokines; Disease Models, Animal; Excitatory Amino Acid Transporter 2; Hyperalgesia; Male; NADP; Neuralgia; Neuroglia; NF-kappa B; Oxidation-Reduction; Paclitaxel; Rats; Rats, Sprague-Dawley; Signal Transduction; Spinal Cord; Tumor Necrosis Factor-alpha | 2014 |